Aspire Biopharma posts investor deck on sublingual drug-delivery platform, lead sublingual aspirin program

Aspire Biopharma Holdings, Inc.

Aspire Biopharma Holdings, Inc.

ASBP

0.00
  • Aspire Biopharma outlined plans to acquire Dura Driver Control Systems for USD 30 million in cash, adding a business with 2025 revenue above USD 200 million.
  • Dura reported 2025 net income above USD 17 million, adjusted EBITDA above USD 22 million, operations across 11 facilities, portfolio of 310+ patents.
  • Lead prescription program OTASA 162 mg sublingual aspirin completed a July 2025 trial, showing therapeutic exposure at least five times faster than chewed tablets.
  • FDA feedback supports a 505(b)(2) filing in Q1 2027; IND planned for September; 32-subject crossover trial targeted for completion by end-2026.
  • Consumer product BUZZ BOMB caffeine launched in Q3 2025; 50 mg sublingual powder format; distribution agreements cited with Amazon, TruLife, Interwest Brokerage.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspire Biopharma Holdings Inc. published the original content used to generate this news brief on June 22, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.